Avapritinib

Brand names: Ayvakit · Active ingredient: Avapritinib

In short: AYVAKIT® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations . AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis

Forms & strengthsTablets: 25 mg, round, white film-coated tablet with debossed text. One side reads "BLU" and the other side reads "25". 50 mg, round, white film-coated tablet with debossed text. One side reads "BLU" and the other side reads "50". …
LabelBlueprint Medicines Corporation
Label updatedOct 26, 2026

What is Avapritinib used for?

AYVAKIT® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations .

AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Limitations of Use:

AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 109/L .

AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).

Limitations of Use:

AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 109/L .

Avapritinib dosage

Administer AYVAKIT orally on an empty stomach, at least 1 hour before or 2 hours after a meal .

Do not make up for a missed dose within 8 hours of the next scheduled dose.

Do not repeat dose if vomiting occurs after AYVAKIT but continue with the next scheduled dose.

Select patients for treatment with AYVAKIT based on the presence of a PDGFRA exon 18 mutation . Information on the FDA-approved test for the detection of PDGFRA D842V mutations is available at: http://www.fda.gov/CompanionDiagnostics.

The recommended dosage of AYVAKIT is 300 mg orally once daily in patients with GIST. Continue treatment until disease progression or unacceptable toxicity.

The recommended dosage of AYVAKIT is 200 mg orally once daily in patients with AdvSM. Continue treatment until disease progression or unacceptable toxicity.

The recommended starting dosage of AYVAKIT is 25 mg orally once daily in patients with ISM. Following at least 6 months of treatment, the dose may be increased to 50 mg once daily as clinically indicated.

The recommended dosage reductions and modifications for adverse reactions are provided in Tables 1 and 2.

Dose Reduction Level | Dosage in patients with GISTPermanently discontinue AYVAKIT in patients with GIST who are unable to tolerate a dose of 100 mg once daily. | Dosage in patients with AdvSMPermanently discontinue AYVAKIT in patients with AdvSM who are unable to tolerate a dose of 25 mg once daily.

First dose reduction | 200 mg once daily | 100 mg once daily

Second dose reduction | 100 mg once daily | 50 mg once daily

Third dose reduction | - | 25 mg once daily

Adverse Reaction | SeveritySeverity as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 | Dosage Modification

Patients with GIST or AdvSM

Intracranial Hemorrhage | Any grade | Permanently discontinue AYVAKIT.

Cognitive Effects | Grade 1 | Continue AYVAKIT at same dose or reduced dose or withhold until improvement to baseline or resolution. Resume at same dose or reduced dose.

Grade 2 or Grade 3 | Withhold AYVAKIT until improvement to baseline, Grade 1, or resolution. Resume at same dose or reduced dose.

Grade 4 | Permanently discontinue AYVAKIT.

Other | Grade 3 or Grade 4 | Withhold AYVAKIT until improvement to less than or equal to Grade 2. Resume at same dose or reduced dose, as clinically appropriate.

Patients with AdvSM

Thrombocytopenia | <50 × 109/L | Interrupt AYVAKIT until platelet count is ≥ 50 × 109/L, then resume at reduced dose (per Table 1). If platelet counts do not recover above 50 × 109/L, consider platelet support.

Avoid concomitant use of AYVAKIT with strong or moderate CYP3A inhibitors. …

How to take Avapritinib — instructions & advice from the label

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Intracranial Hemorrhage

Advise patients to contact their healthcare provider immediately if experiencing neurological signs and symptoms that may be associated with intracranial hemorrhage (i.e., severe headache, vomiting, drowsiness, dizziness, confusion, slurred speech, or paralysis) .

Inform patients with AdvSM of the need to monitor platelet counts before and during treatment .

Cognitive Effects

Advise patients and caretakers to notify their healthcare provider if they experience new or worsening cognitive symptoms. Advise patients not to drive or operate hazardous machinery if they are experiencing cognitive adverse reactions .

Photosensitivity

Inform patients that there is a potential risk of photosensitivity reactions with AYVAKIT. Advise patients to limit direct ultraviolet exposure by using sunscreen and protective clothing during treatment with AYVAKIT .

Embryo-Fetal Toxicity

Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy . …

Warnings & precautions

Do not take this medicine if: None.

Serious intracranial hemorrhage may occur with AYVAKIT treatment; fatal events occurred in less than 1% of patients. Overall, intracranial hemorrhage (e.g., subdural hematoma, intracranial hemorrhage, and cerebral hemorrhage) occurred in 2.9% of the 749 patients with GIST or AdvSM who received AYVAKIT in clinical trials. No events of intracranial hemorrhage occurred in the 246 patients with ISM who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of intracranial hemorrhage which may include history of vascular aneurysm, intracranial hemorrhage or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of intracranial hemorrhage may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of intracranial hemorrhage.

Permanently discontinue AYVAKIT if intracranial hemorrhage of any grade occurs .

Gastrointestinal Stromal Tumors

Intracranial hemorrhage occurred in 3 of 267 patients (1.1%). Two (0.7%) of the events were Grade ≥ 3 and resulted in discontinuation of study drug. Events of intracranial hemorrhage occurred in a range from 1.7 months to 19.3 months after initiating AYVAKIT.

Advanced Systemic Mastocytosis

In patients with AdvSM who received AYVAKIT at 200 mg daily, intracranial hemorrhage occurred in 2 of 75 patients (2.7%) who had platelet counts ≥ 50 × 109/L prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts.

In patients with AdvSM, a platelet count must be performed prior to initiating therapy; AYVAKIT is not recommended in patients with AdvSM with platelet counts < 50 × 109/L. …

Avapritinib side effects

The following clinically significant adverse reactions are described elsewhere in the labeling:

Intracranial hemorrhage

Cognitive effects

Photosensitivity

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data in the WARNINGS AND PRECAUTIONS reflect exposure to AYVAKIT at 25 mg to 600 mg orally once daily in 995 patients enrolled in one of five clinical trials conducted in patients with advanced malignancies and systemic mastocytosis, including NAVIGATOR, EXPLORER, PATHFINDER and PIONEER . These patients included 601 patients with GIST, 148 patients with AdvSM and 246 patients with ISM. Among the 995 patients receiving AYVAKIT, 54% were exposed for 6 months or longer and 26% were exposed for greater than 1 year.

Gastrointestinal Stromal Tumors

Unresectable or Metastatic GIST

The safety of AYVAKIT in patients with unresectable or metastatic GIST was evaluated in NAVIGATOR . The trial excluded patients with history of cerebrovascular accident or transient ischemic attacks, known risk of intracranial bleeding, and metastases to the brain. Patients received AYVAKIT 300 mg or 400 mg orally once daily (n = 204). Among patients receiving AYVAKIT, 56% were exposed for 6 months or longer and 44% were exposed for greater than one year. …

Drug interactions

Strong and Moderate CYP3A Inhibitors

Coadministration of AYVAKIT with a strong or moderate CYP3A inhibitor increases avapritinib plasma concentrations , which may increase the incidence and severity of adverse reactions of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration of AYVAKIT with a moderate CYP3A inhibitor cannot be avoided, reduce the dose of AYVAKIT .

Strong and Moderate CYP3A Inducers

Coadministration of AYVAKIT with a strong or moderate CYP3A inducer decreases avapritinib plasma concentrations , which may decrease efficacy of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers.

Hormonal Contraceptives

Coadministration of AYVAKIT with ethinyl estradiol-containing contraceptives may increase the exposure of ethinyl estradiol, which may lead to increased risk of ethinyl estradiol-associated adverse reactions .

If the patient is unable to use or tolerate an effective nonhormonal contraceptive or an effective hormonal contraceptive without estrogen, use a formulation of ethinyl estradiol containing 20 mcg or less unless a higher dose is necessary. …

About this medicine

Avapritinib is a kinase inhibitor with the chemical name (S)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1H-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazin-yl)pyrimidin-5-yl)ethan-1-amine. The molecular formula is C26H27FN10, and the molecular weight is 498.57 g/mol. Avapritinib has the following chemical structure:

The solubility of avapritinib in 0.1N HCl (pH 1.0) and buffer solutions at pH 2.5, 4.0, and 7.0 (at 25°C) is 3.6 mg/mL, 0.14 mg/mL, 0.07 mg/mL and <0.001 mg/mL respectively, indicating a decrease in solubility with increasing pH.

AYVAKIT (avapritinib) film-coated tablets for oral use are supplied with five strengths that contain 25 mg, 50 mg, 100 mg, 200 mg or 300 mg of avapritinib. The tablets also contain inactive ingredients: copovidone, croscarmellose sodium, magnesium stearate, and microcrystalline cellulose. The tablet coating consists of polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 645c887c-8cd4-4623-8da9-ac223d71a8b9. Read the full official label on DailyMed.

Related medicines

Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate